The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Open accessAbstract
Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major depression, the majority of treated individuals fail to achieve full syndromal and functional recovery with the index and subsequent pharmacological treatments. Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to providing hope to affected persons, these agents represent the first non-monoaminergic agents with proven rapid-onset efficacy in major depressive disorder. Nevertheless, concerns remain about the safety and tolerability of ketamine and esketamine in mood disorders. Moreover, there is uncertainty about the appropriate position of these agents in treatment algorithms, their comparative effectiveness, and the appropriate setting, infrastructure, and personnel required for their competent and safe implementation. In this article, an international group of mood disorder experts provides a synthesis of the literature with respect to the efficacy, safety, and tolerability of ketamine and esketamine in adults with treatment-resistant depression. The authors also provide guidance for the implementation of these agents in clinical practice, with particular attention to practice parameters at point of care. Areas of consensus and future research vistas are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Available evidence also indicates that the efficacy of ketamine/esketamine in the acute treat ment of TRD is also apparent in individuals with greater de grees of antidepressant resistance 205 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [205]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The risks for the foregoing safety concerns would be expected to be mitigated when administering ketamine/esketamine under medical supervision in accordance with best practices 205 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [205]
In the citing paper
“This result is in line with a recent review of literature emphasising that tolerance of ketamine is good.32”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citationSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citationKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationMcIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795 · cited 2×
“Intranasal esketamine combined with a conventional antidepressant decreased the risk of relapse by 51% among personswhohad achieved stable remission and 70% among those who achieved a stable responsewithacute therapy (60).”
BackgroundSelf-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Self-citationMcIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationMalhotra, A. K. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 681
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Self-citationFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Self-citationSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Self-citationAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Self-citationA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
Self-citationFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Self-citationAnand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Lee, Y. L., Ragguett, R., Mansur, R. B., Boutilier, J. J., Rosenblat, J. D., Trevizol, A. P., Brietzke, E. M., Lin, K., Pan, Z., Subramaniapillai, M., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.073 · Cited by 418
Self-citationIonescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Self-citationBahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Self-citationRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m13191 · Cited by 376 · cited 1×
“Notwithstanding the failure to detect a difference in suicidal ideation, the studiesprovided thebasis for theFDAapproval of esketamine for the treatment of major depressive disorder withsuicidal ideationorbehavior (77, 78).”
BackgroundSelf-citationKetamine-Associated Ulcerative Cystitis: A New Clinical Entity
Shahani, R., Streutker, C. J., Dickson, B. C., & Stewart, R. J. (2007) · Urology · doi:10.1016/j.urology.2007.01.038 · Cited by 375
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citationAcute and chronic effects of ketamine upon human memory: a review
Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 309
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308 · cited 3×
“It is reassuring that a long-term study with intranasal esketamine did not identify a significant percentage of individuals experiencing genitourinary symptoms (100, 101).”
BackgroundSelf-citationKetamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
Self-citationMathew, S. J., Murrough, J. W., Rot, M. A. H., Collins, K. A., Reich, D. L., & Charney, D. S. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 297
Self-citationDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283
Self-citationMcAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citationLoo, C. K. A., Gálvez, V., O’Keefe, E. J., Mitchell, P. B., Hadzi‐Pavlovic, D., Leyden, J., Harper, S., Somogyi, A. A., Lai, R., Weickert, C. S., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12572 · Cited by 258
The prevalence and natural history of urinary symptoms among recreational ketamine users
WINSTOCK, A. R., Mitcheson, L., Gillatt, D. A., & Cottrell, A. M. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11028.x · Cited by 217
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
Self-citationPerlman, K., Benrimoh, D. A., Israel, S. A., Rollins, C. P. E., Brown, E. H., Tunteng, J.-F., You, R., You, E. L., Tanguay-Sela, M., Snook, E., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.067 · Cited by 193
Correia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Ibrahim, L. A., Diazgranados, N., Luckenbaugh, D. A., Machado‐Vieira, R., Baumann, J., Mallinger, A. G., & Zarate, C. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.019 · Cited by 191
Self-citationThe effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
McIntyre, R. S., Carvalho, I. P., Lui, L. M. W., Majeed, A., Masand, P. S., Gill, H., Rodrigues, N. B., Lipsitz, O., Coles, A. C., Lee, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.050 · Cited by 187
Self-citationDakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101123 · Cited by 186
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0644-9 · Cited by 184
Self-citationDakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070684 · Cited by 183
Rosenblat, J. D., & McIntyre, R. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.042 · Cited by 179
Self-citationIonescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
The Mu-Opioid Receptor and the NMDA Receptor Associate in PAG Neurons: Implications in Pain Control
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Vicente‐Sánchez, A., Berrocoso, E., & Garzón, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.155 · Cited by 170
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Self-citationSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Self-citationKryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159
Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
Self-citationEsketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
Ballard, E. D., Wills, K. E., Lally, N., Richards, E. M., Luckenbaugh, D. A., Walls, T. L., Ameli, R., Niciu, M. J., Brutsché, N. E., Park, L., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.057 · Cited by 155
Self-citationYoon, G., Petrakis, I. L., & Krystal, J. H. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3990 · Cited by 155
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
Self-citationEsketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
Toljan, K., & Vrooman, B. (2018) · Medical Sciences · doi:10.3390/medsci6040082 · Cited by 146
Murrough, J. W., Burdick, K. E., Levitch, C. F., Perez, A. M., Brallier, J. W., Chang, L. C., Foulkes, A., Charney, D. S., Mathew, S. J., & Iosifescu, D. V. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.298 · Cited by 142
Self-citationPhillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owoeye, O., Batten, L. A., & Blier, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0570-x · Cited by 139 · cited 1×
“A limitation, however, is the lackof evidencedemonstrating reduction insuicidecompletionandwhetheramorepersistent reduction in suicidal ideation is observed beyond 6 weeks for either esketamine or ketamine (74).”
BackgroundZhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04198.x · Cited by 137
Niciu, M. J., Shovestul, B. J., Jaso, B. A., Farmer, C., Luckenbaugh, D. A., Brutsché, N. E., Park, L. T., Ballard, E. D., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.049 · Cited by 137
Self-citationGastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
van Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
Neuroimaging-based biomarkers for treatment selection in major depressive disorder
Dunlop, B. W., & Mayberg, H. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/bdunlop · Cited by 127
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders
Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17020239 · Cited by 125
Self-citationXiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J. D., Rodrigues, N. B., Carvalho, I., Lui, L. M. W., Gill, H., Narsi, F., Mansur, R. B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.038 · Cited by 124
Self-citationWilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L. R., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457960 · Cited by 122
Self-citationMontgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Alexander, L., Gaskin, P. L. R., Sawiak, S. J., Fryer, T. D., Hong, Y. T., Cockcroft, G. J., Clarke, H. F., & Roberts, A. C. (2019) · Neuron · doi:10.1016/j.neuron.2018.11.021 · Cited by 120
Cusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N. E., Eikermann, M., Durham, K. E., Swee, M. B., Chang, T. E., et al. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 114
Rong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114
Self-citationRosenblat, J. D., Carvalho, A. F., Li, M., Lee, Y. L., Subramanieapillai, M., & McIntyre, R. S. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18r12475 · Cited by 114
Self-citationMurrough, J. W., Wan, L.-B., Iacoviello, B. M., Collins, K. A., SOLON, C. A., Glicksberg, B. S., Perez, A. M., Mathew, S. J., Charney, D. S., Iosifescu, D. V., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3255-x · Cited by 113
Self-citationMcIntyre, R. S., Rodrigues, N. B., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L. M. W., Senyk, O., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.088 · Cited by 110
Self-citationEfficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis
Papakostas, G. I., Salloum, N. C., Hock, R. S., Jha, M. K., Murrough, J. W., Mathew, S. J., Iosifescu, D. V., & Fava, M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19r12889 · Cited by 108
Self-citationPossible pathophysiology of ketamine‐related cystitis and associated treatment strategies
Jhang, J., Hsu, Y., & Kuo, H. (2015) · International Journal of Urology · doi:10.1111/iju.12841 · Cited by 106
Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L. M., & Curran, H. V. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1656-y · Cited by 106
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression
Morris, L. S., Costi, S., Tan, A., Stern, E. R., Charney, D. S., & Murrough, J. W. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0591-5 · Cited by 104
Self-citationA Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 102
A Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Gill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93
Self-citationTreating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y. L., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 85
Self-citationDomany, Y., Shelton, R. C., & McCullumsmith, C. B. (2020) · Depression and Anxiety · doi:10.1002/da.22975 · Cited by 84
Zhang, Y., Zhang, T., Guo, C., Lv, J., Hua, Z., Hou, S., Zhang, Y., Meng, W., & Xu, J. F. (2016) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2016.11.101 · Cited by 78
van Schalkwyk, G. I., Wilkinson, S. T., Davidson, L., Silverman, W. K., & Sanacora, G. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.023 · Cited by 77
Self-citationAttentional bias to incentive stimuli in frequent ketamine users
Morgan, C. J. A., Rees, H., & Curran, H. V. (2008) · Psychological Medicine · doi:10.1017/s0033291707002450 · Cited by 76
Improving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040398 · Cited by 76
Self-citationFrye, M. A., Blier, P., & Tye, S. J. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000316 · Cited by 75
Gilbert, J. R., & Zarate, C. A. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172856 · Cited by 75
Self-citationA New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
Self-citationRavikrishnan, A., Gandhi, P. J., Shelkar, G. P., Liu, J., Pavuluri, R., & Dravid, S. M. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.011 · Cited by 73
Morrison, R. L., Fedgchin, M. M., Singh, J. B., van Gerven, J., Zuiker, R. G. J. A., Lim, K. S., van der Ark, P. D., Wajs, E., Xi, L., Zannikos, P., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4828-5 · Cited by 73
Protti, M., Mandrioli, R., Marasca, C., Cavalli, A., Serretti, A., & Mercolini, L. (2020) · Medicinal Research Reviews · doi:10.1002/med.21671 · Cited by 71
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., Saah, T. C., Dunlop, B. W., & McDonald, W. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.025 · Cited by 70
Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00699-4 · Cited by 68
Zhang, M. W., Harris, K. M., & Ho, R. (2016) · BMC Medical Ethics · doi:10.1186/s12910-016-0087-3 · Cited by 67
Self-citationMcIntyre, R. S., Lipsitz, O., Rodrigues, N. B., Lee, Y., Cha, D. S., Vinberg, M., Lin, K., Malhi, G. S., Subramaniapillai, M., Kratiuk, K., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.12941 · Cited by 66
Self-citationMcIntyre, R. S., Millson, B., & Power, G. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.045 · Cited by 60
Self-citationMathew, S. J., Wilkinson, S. T., Altinay, M. I., Asghar‐Ali, A. A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.12.009 · Cited by 59
Self-citationCosti, S., Soleimani, L., Glasgow, A., Brallier, J., Spivack, J., Schwartz, J., Levitch, C. F., Richards, S., Hoch, M., Stade, E. C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0365-0 · Cited by 56
Self-citationGrabski, M., Borissova, A., Marsh, B., Morgan, C. J. A., & Curran, H. V. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112629 · Cited by 55
Are we repeating mistakes of the past? A review of the evidence for esketamine
Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2020.89 · Cited by 53
Salloum, N. C., D, M. F. M., Freeman, M. P., Flynn, M., Hoeppner, B. B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2018) · Depression and Anxiety · doi:10.1002/da.22875 · Cited by 52
Self-citationThe Influence of Anesthetic Agents on Rat Hepatic Cytochromes P450 in vivo
Loch, J. M., Potter, J., & Bachmann, K. A. (2008) · Pharmacology · doi:10.1159/000139276 · Cited by 52
Rodrigues, N. B., McIntyre, R. S., Lipsitz, O., Lee, Y. L., Cha, D. S., Nasri, F., Gill, H., Lui, L. M. W., Subramaniapillai, M., Kratiuk, K., et al. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1776699 · Cited by 51
Self-citationRoss, E. L., & Soeteman, D. I. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900625 · Cited by 51
Genitourinary toxicity of ketamine
Wei, Y., Yang, J., Yin, Z., Guo, Q., Liang, B., & Zhou, K.-Q. (2013) · Hong Kong Medical Journal · doi:10.12809/hkmj134013 · Cited by 51
Genome-wide association study and polygenic risk score analysis of esketamine treatment response
Li, Q. S., Wajs, E., Ochs-Ross, R., Singh, J. B., & Drevets, W. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-69291-6 · Cited by 49
Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11802 · Cited by 48
Can a Framework Be Established for the Safe Use of Ketamine?
Freedman, R., Brown, A. S., Cannon, T. D., Druss, B. G., Earls, F. J., Escobar, J. I., Hurd, Y. L., Lewis, D. A., López‐Jaramillo, C., Luby, J. L., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030290 · Cited by 47
Self-citationCarter, B., Strawbridge, R., Husain, M. I., Jones, B. D. M., Short, R., Cleare, A. J., Tsapekos, D., Patrick, F., Marwood, L., Taylor, R. W., et al. (2020) · International Review of Psychiatry · doi:10.1080/09540261.2020.1765748 · Cited by 47
Self-citationBody Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Freeman, M. P., Hock, R. S., Papakostas, G. I., Judge, H., Cusin, C., Mathew, S. J., Sanacora, G., Iosifescu, D. V., DeBattista, C., Trivedi, M. H., et al. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001209 · Cited by 44
Self-citationAlbott, C. S., Shiroma, P. R., Cullen, K. R., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16l11277 · Cited by 42
Successful Use of Ketamine for the Treatment of Psychotic Depression in a Teenager
Zarrinnegar, P., Kothari, J. S., & Cheng, K. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0028 · Cited by 41
Lipsitz, O., Di Vincenzo, J. D., Rodrigues, N. B., Cha, D. S., Lee, Y., Greenberg, D., Teopiz, K. M., Ho, R. C., Cao, B., Lin, K., et al. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.12.032 · Cited by 40
Self-citationInfluence of urethane and ketamine on rat hepatic cytochrome P450 in vivo
Meneguz, A., Fortuna, S., Lorenzini, P., & Volpe, M. T. (1999) · Experimental and Toxicologic Pathology · doi:10.1016/s0940-2993(99)80027-x · Cited by 40
Szarmach, J., Cubała, W. J., Włodarczyk, A., & Wiglusz, M. S. (2019) · PubMed · Cited by 38
Neurobiological biomarkers of response to ketamine
Kadriu, B., Ballard, E. D., Henter, I. D., Murata, S., Gerlus, N., & Zarate, C. A. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.003 · Cited by 36
Self-citationKheirabadi, D., Kheirabadi, G., Vafaie, M., Mirlouhi, Z., & Hajiannasab, R. (2019) · Advanced Biomedical Research · doi:10.4103/abr.abr_166_18 · Cited by 35
Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series
Ajub, E., & Lacerda, A. L. T. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.011 · Cited by 35
The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms
Ribeiro, C. M. D. F., Sanacora, G., Hoffman, R. E., & Ostroff, R. B. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.016 · Cited by 34
Self-citationKetamine for Treatment-Resistant Depression
Zarate Jr, C. A., & Mathew, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0 · Cited by 34
Salloum, N. C., D, M. F. M., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B. B., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.017 · Cited by 34
Self-citationDold, M., Bartova, L., & Kasper, S. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa034 · Cited by 34
Self-citationRapid acting antidepressants in the mTOR pathway: Current evidence
Athira, K. V., Mohan, A. S., & Chakravarty, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.022 · Cited by 34
Ng, J., Lui, L. M. W., Rosenblat, J. D., Teopiz, K. M., Lipsitz, O., Cha, D. S., Xiong, J., Nasri, F., Lee, Y. L., Kratiuk, K., et al. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05767-1 · Cited by 34
Self-citationCanuso, C. M., Singh, J. B., Fedgchin, M. M., Alphs, L. D., Lane, R., Lim, P., Pinter, C., Hough, D. W., Sanacora, G., Manji, H. K., et al. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17105 · Cited by 32
Self-citationKetamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion
Pennybaker, S. J., Luckenbaugh, D. A., Park, L. T., Marquardt, C. A., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.08.041 · Cited by 31
Self-citationOral Ketamine for Depression, 1
Andrade, C. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19f12820 · Cited by 30
Narita, M., Hashimoto, K., Amano, T., Narita, M., Niikura, K., Nakamura, A., & Suzuki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05059.x · Cited by 29
Urothelial toxicity of esketamine in the treatment of depression
Findeis, H., Sauer, C., Cleare, A. J., Bauer, M., & Ritter, P. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05611-y · Cited by 29
Phillips, J. L., Jaworska, N., Kamler, E., Bhat, V., Blier, J., Foster, J. A., Hassel, S., Ho, K. T., McMurray, L., Milev, R. V., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02672-3 · Cited by 24
Lipsitz, O., McIntyre, R. S., Rodrigues, N. B., Lee, Y. L., Gill, H., Subramaniapillai, M., Kratiuk, K., Nasri, F., Mansur, R. B., & Rosenblat, J. D. (2020) · CNS Spectrums · doi:10.1017/s1092852920002102 · Cited by 24
Self-citationBenzodiazepines may reduce the effectiveness of ketamine in the treatment of depression
Ford, N., Ludbrook, G., & Galletly, C. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415590631 · Cited by 23
Katz, R., Toprak, M., Wilkinson, S. T., Sanacora, G., & Ostroff, R. B. (2018) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.05.007 · Cited by 23
Self-citationChen, Q., Dong, J., Luo, J., Ren, L., Min, S., Hao, X., Luo, Q., Chen, J., & Li, X. (2020) · Journal of Ect · doi:10.1097/yct.0000000000000636 · Cited by 22
S -ketamine compared to etomidate during electroconvulsive therapy in major depression
Zavorotnyy, M., Kluge, I., Ahrens, K., Wohltmann, T., Köhnlein, B., Dietsche, P., Dannlowski, U., Kircher, T. T. J., & Konrad, C. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0800-3 · Cited by 21
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030273 · Cited by 21
Maintaining Rapid Antidepressant Effects Following Ketamine Infusion
Papakostas, G. I. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19r12859 · Cited by 20
Self-citationSingh, B., Bobo, W. V., Rasmussen, K. G., Stoppel, C. J., Rico, J. A. Q., Schak, K. M., Biernacka, J. M., Frye, M. A., & Voort, J. L. V. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19l12852 · Cited by 20
George, M. S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070800 · Cited by 19
Chan, L. F., Eu, C. L., Soh, S. Y., Maniam, T., Kadir, Z. S., Chong, B. T. W., Loo, J. L., Sharip, S., WONG, V. C. W., Loo, T. H., et al. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000316 · Cited by 19
Singh, J. B., Fedgchin, M. M., Daly, E., & Drevets, W. C. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.002 · Cited by 18
Heifets, B. D., Williams, N., Bentzley, B. S., & Schatzberg, A. F. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0766 · Cited by 17
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation
Rodrigues, N. B., Siegel, A., Lipsitz, O., Cha, D. S., Gill, H., Nasri, F., Simonson, K., Shekotikhina, M., Lee, Y., Subramaniapillai, M., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852920002187 · Cited by 17
Self-citationRapid antidepressant effect of S-ketamine in schizophrenia
Bartova, L., Papageorgiou, K., Milenković, I., Dold, M., Weidenauer, A., Willeit, M., Winkler, D., & Kasper, S. F. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.05.007 · Cited by 16
Self-citationNew medications for treatment-resistant depression: a brief review of recent developments
Thase, M. E. (2017) · CNS Spectrums · doi:10.1017/s1092852917000876 · Cited by 15
Self-citationWang, J. C. C., & Swainson, J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001244 · Cited by 14
Lin, F., He, Y., Zhang, L., Zhang, M., Zhang, Y., & Wen, C. (2015) · Europe PMC (PubMed Central) · Cited by 12
Opioid Receptor μ-1 and Ketamine Effects in a Suicidal Depression Trial
Grunebaum, M. F., Galfalvy, H., Liu, J., Huang, Y., Marcott, S., Burke, A. K., & Mann, J. J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001237 · Cited by 11
Tratamientos disruptivos en psiquiatría
Vieta, E. (2019) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2019.10.001 · Cited by 10
Self-citationLi, K., & Loshak, H. (2019) · Europe PMC (PubMed Central) · Cited by 10
The use of ketamine in electroconvulsive therapy
Kucia, K. A., & Merk, W. (2015) · Psychiatria Polska · doi:10.12740/pp/31748 · Cited by 9
More Thoughts on Intranasal Esketamine: Response to Drevets et al.
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070688r · Cited by 7
Disruptive treatments in psychiatry
Vieta, E. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2019.10.003 · Cited by 6
Self-citationLetter to BJPsych in response to Horowitz and Moncrieff
Kasper, S. F., Young, A. H., Vieta, E., Goodwin, G., & Meyer‐Lindenberg, A. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.161 · Cited by 2
Self-citation
Research works printed but not linked: 12
- Toljan K, 2018, Med Sci (Basel), 6, 82
- Lin F, 2015, Int J Clin Exp Med, 8, 4335
- Szarmach J, 2019, Psychiatr Danub, 31, 585
- Andrade C, 2019, J Clin Psychiatry, 80, 19f12820
- Canuso CM, 2019, Focus Am Psychiatr Publ, 17, 55
- Wei YB, 2013, Hong Kong Med J, 19, 341
- Morgan CJA, 2004, Psychopharmacology (Berl), 172, 298
- Health Quality Ontario, 2016, Ont Health Technol Assess Ser, 16, 1
- Rodrigues NB, CNS Spectr
- Ng J, Psychopharmacology (Berl)
- Rodrigues NB, CNS Spectr
- Lipsitz O, CNS Spectr
Cited by
Sorted by citations
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationGukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M. I., Aloysi, A. S., Asghar‐Ali, A. A., Barnett, B. S., Chang, L. C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302399 · Cited by 294
Self-citationAlnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Self-citationAbbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., et al. (2022) · BMJ · doi:10.1136/bmj-2021-067194 · Cited by 181
Self-citation
Metadata
- Authors
- McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., Thase, M., Vieta, E., Young, A. H., Zarate, C. A., & Stahl, S.
- Affiliations
- University Health Network (CA)
- Mood Disorders Psychopharmacology Unit, University Health Network, Toronto (McIntyre, Rosenblat, Y. Lee, Lui, Mansur); Department of Psychiatry, University of Toronto, Toronto (McIntyre, Rosenblat, Mansur); Department of Pharmacology, University of Toronto, Toronto (McIntyre); Brain and Cognition Discovery Foundation, Toronto (McIntyre, Subramaniapillai); Canadian Rapid Treatment Center of Excellence, Mississauga, Ontario (Rosenblat, Kratiuk); Department of Psychiatry and Behavioral Sciences, Austin Dell...
- ORCID
- McIntyre, Roger S.
- Rosenblat, Joshua D.
- Nemeroff, Charles B.
- Sanacora, Gerard
- Murrough, James W.
- Brietzke, Elisa
- Dodd, Seetal
- Gorwood, Philip
- Ho, Roger
- Iosifescu, Dan V.
- Kasper, Siegfried
- Kratiuk, Kevin
- Lee, Jung Goo
- Lee, Yena
- Lui, Leanna M.W.
- Mansur, Rodrigo B.
- Papakostas, George I.
- Subramaniapillai, Mehala
- Thase, Michael
- Vieta, Eduard
- Young, Allan H.
- Zarate, Carlos A.
- Stahl, Stephen
- Venue
- American Journal of Psychiatry
- Published
- 2021-05-01
- Volume
- 178
- Issue
- 5
- Pages
- 383-399
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC9635017
- OpenAlex
- W3137976016
- Semantic Scholar
- 3cd087ef6947b39c8c924b7248d9d40de77b9e44
- Cited by
- 731
- References
- 168
- Citations by year
- 2026: 129 · 2025: 167 · 2024: 165 · 2023: 141 · 2022: 83 · 2021: 44
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NIHR202380)
- National Institutes of Health (Z99 MH999999)
- National Institute of Mental Health (ZIAMH002857, ZIAMH002927)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, treatment-resistant depression, major depressive disorder, drug safety and tolerability, clinical implementation, treatment algorithm, expert consensus
- MeSH terms
- Implementation Science, Antidepressive Agents, Delivery of Health Care, Depressive Disorder, Major, Major Depressive Disorder, Dissociative Disorders, Humans, Hypertension, Ketamine, Monitoring, Physiologic, Personnel Staffing and Scheduling, Psychoses, Substance-Induced, Patient Selection, Excitatory Amino Acid Antagonists, Substance-Related Disorders, Suicidal Ideation, Lower Urinary Tract Symptoms, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
